PET显像在胃肠胰神经内分泌肿瘤中的应用现状与前景
胃肠胰神经内分泌肿瘤(GEP-NETs)发病率逐年上升,精准定位与分期依赖多学科影像,其中PET/CT处于前沿。GEP-NETs的病理生理特征可作为高特异性分子靶点,通过PET放射性药物实现诊断、分期、疗效监测及预后评估。双示踪剂(18F-FDG与68Ga-DOTA-肽)PET/CT是目前最佳诊断策略,可无创全身评估肿瘤异质性并指导治疗决策。
要点
- 双示踪剂18F-FDG与68Ga-DOTA-肽PET/CT是GEP-NETs当前最佳诊断策略。
- 64Cu-DOTATATE已获FDA批准用于SSTR阳性NETs,具诊断与后勤优势。
- 18F-DOPA可用于不表达SSTR且形态学阴性的血清素分泌型GEP-NETs。
诊断标准与关键数值
- 双示踪剂(18F-FDG与68Ga-DOTA-肽)PET/CT为当前最佳诊断影像策略。
- 64Cu-DOTATATE近期获FDA批准用于SSTR阳性NETs。
- 18F-DOPA适用于不表达SSTR且形态学阴性的血清素分泌型GEP-NETs。
- 临床怀疑胰岛素瘤而形态学或SSTR PET/CT阴性时,可考虑GLP-1R靶向PET/CT。
临床应用与阅片要点
- 对GEP-NETs应优先考虑双示踪剂PET/CT以全面评估肿瘤异质性与全身负荷。
- 报告需结合示踪剂摄取特征提示肿瘤分化程度与治疗反应。
- 对形态学阴性但临床怀疑胰岛素瘤者,建议补充GLP-1R靶向PET/CT。
局限性
- 本文为综述,未提供原始研究数据或系统评价证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) represent a heterogeneous group of rare neoplasms with increasing incidence over the last decades. Localization of GEP-NETs and their metastases is a vital component for the implementation of accurate and patient-tailored treatment strategies. Addressing this challenge requires the employment of multidisciplinary imaging approaches, with hybrid positron emission tomography/computed tomography (PET/CT) imaging techniques standing at the forefront of this effort. GEP-NETs exhibit several pathophysiologic characteristics, which can serve as highly specific molecular targets that can be effectively visualized and quantified by means of PET-radiopharmaceuticals, facilitating diagnosis, accurate staging and efficient monitoring of treatment response. Furthermore, the capability for whole-body, in-vivo, non-invasive characterization of the molecular heterogeneity of the disease, provides strong prognostic information, while enabling the selection of patients suitable for precision-based theranostic approaches. The dual tracer (18F-FDG & 68Ga-DOTA-peptides) PET/CT imaging approach is the current optimal diagnostic imaging strategy, since it enables tumor localization, accurate staging, non-invasive whole-body total tumor burden characterization of disease heterogeneity, while providing strong prognostic information and guidance towards treatment strategy. Moreover, 64Cu-DOTATATE has been recently approved by FDA for SSTRs positive NETs, promising substantial diagnostic and logistical benefits. Furthermore, 18F-DOPA offers diagnostic capabilities for serotonin-secreting GEP-NETs which are not characterized by cell-surface over-expression of somatostatin receptors (SSTRs) and cannot be seen on morphological imaging. In addition, PET/CT with agents targeting the expression of glucagon-like peptide-1 receptor (GLP-R1) should be considered in cases of clinical suspicion for insulinomas that cannot be detected by morphological imaging or STTRs PET/CT imaging.
引用
- Papadakis GZ, Karantanas AH, Marias K, et al. Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). Eur J Radiol. 2021. PMID: 34482177. doi:10.1016/j.ejrad.2021.109932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。